In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Talaris Therapeutics (TALS – Research Report), with a price target of $12.00. The company’s shares closed last Friday at $1.34.
According to TipRanks, Selvaraju is an analyst with an average return of -24.6% and a 27.15% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Cocrystal Pharma, Enlivex, and ADMA Biologics.
The word on The Street in general, suggests a Hold analyst consensus rating for Talaris Therapeutics with a $2.00 average price target.
See today’s best-performing stocks on TipRanks >>
TALS market cap is currently $55.91M and has a P/E ratio of -0.79.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
